3:22 PM
 | 
Sep 11, 2018
 |  BC Extra  |  Financial News

OncoResponse to move into clinic with $40M series B

OncoResponse Inc. (Houston, Texas) raised $40 million in a series B round led by RiverVest Venture Partners. Fellow new investors Qatar Investment Authority and Redmile Group participated, as did existing investors Alexandria Venture Investments, Arch Venture Partners, HT Family Office, Canaan Partners, Helsinn Investment Fund and William Marsh Rice University.

OncoResponse told BioCentury the round will give it runway into 2021, at which point the company expects to have two cancer immunotherapy programs in the clinic, with data in hand for one of the programs. The company declined to disclose details about its pipeline but said the candidates will be used in combination with PD-1 and PD-L1 inhibitors.

OncoResponse, a JV launched in 2015 by Theraclone Sciences Inc. (Seattle, Wash.) and University of Texas MD Anderson Cancer Center, is repurposing Theraclone's I-STAR discovery platform to identify antibodies produced by exceptional responders to cancer immunotherapy. By tapping patients' natural immune responses, OncoResponse hopes to find novel immune targets and anticancer antibodies that can be engineered into antibody-drug conjugates or bispecific antibodies (see “Interrogating Immunity”).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD